Understanding how some acute myeloid leukemia cells resist treatment
Kinase-independent mechanism of resistance to FLT3 inhibitors in AML
This study is looking at how a specific mutation in acute myeloid leukemia cells helps them resist treatment with FLT3 inhibitors, and it aims to find new ways to help patients overcome this resistance.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10813146 on NIH RePORTER |
What this research studies
This research investigates how certain mutations in acute myeloid leukemia (AML) cells allow them to survive despite treatment with FLT3 inhibitors. The study focuses on the FLT3-F691L mutation, which has been linked to treatment resistance. By examining both kinase-dependent and independent signaling pathways, the researchers aim to uncover the mechanisms that enable these cancer cells to continue growing. The findings could lead to new therapeutic strategies to overcome resistance in AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have FLT3 mutations.
Not a fit: Patients with acute myeloid leukemia who do not have FLT3 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with FLT3-mutant acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results in understanding resistance mechanisms in cancer therapies, suggesting that this approach could yield valuable insights.
Where this research is happening
Cincinnati, United States
- Cincinnati Childrens Hosp Med Ctr — Cincinnati, United States (Active)
Researchers
- Principal investigator: Jones, Laquita M — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Jones, Laquita M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.